Chromogenic in Situ Hybridisation (CISH) Should Be an Accepted Method in the Routine Diagnostic Evaluation of HER2 Status in Breast Cancer

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2007 Feb 13

PMID 17293390

Citations 12

Authors

S Di Palma

N Collins

C Faulkes

B Ping

G Ferns

B Haagsma

G Layer

M W Kissin

M G Cook

Affiliations

Soon will be listed here.

Citing Articles

Review of In Situ Hybridization (ISH) Stain Images Using Computational Techniques.

Rehman Z, Fauzi M, Wan Ahmad W, Abas F, Cheah P, Chiew S Diagnostics (Basel). 2024; 14(18).

PMID: 39335767 PMC: 11430898. DOI: 10.3390/diagnostics14182089.

Insights into brain tumor diagnosis: exploring hybridization techniques.

Namiot E, Zembatov G, Tregub P Front Neurol. 2024; 15:1393572.

PMID: 39022728 PMC: 11252041. DOI: 10.3389/fneur.2024.1393572.

Progress on deep learning in digital pathology of breast cancer: a narrative review.

Zhu J, Liu M, Li X Gland Surg. 2022; 11(4):751-766.

PMID: 35531111 PMC: 9068546. DOI: 10.21037/gs-22-11.

Targeted therapeutic options and future perspectives for HER2-positive breast cancer.

Wang J, Xu B Signal Transduct Target Ther. 2019; 4:34.

PMID: 31637013 PMC: 6799843. DOI: 10.1038/s41392-019-0069-2.

Evaluating Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma.

Atabati H, Raoofi A, Amini A, Masteri Farahani R Open Access Maced J Med Sci. 2018; 6(11):1977-1981.

PMID: 30559846 PMC: 6290434. DOI: 10.3889/oamjms.2018.455.

References

Dandachi N, Dietze O, Hauser-Kronberger C . Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 2002; 82(8):1007-14. DOI: 10.1097/01.lab.0000024360.48464.a4. View

Hanna W, Kwok K . Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol. 2006; 19(4):481-7. DOI: 10.1038/modpathol.3800555. View

Elkin E, Weinstein M, Winer E, M Kuntz K, Schnitt S, Weeks J . HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004; 22(5):854-63. DOI: 10.1200/JCO.2004.04.158. View

Ellis I, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K . Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol. 2004; 57(3):233-7. PMC: 1770242. DOI: 10.1136/jcp.2003.007724. View

Isola J, Tanner M, Forsyth A, Cooke T, Watters A, Bartlett J . Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res. 2004; 10(14):4793-8. DOI: 10.1158/1078-0432.CCR-0428-03. View

Hauser-Kronberger C, Dandachi N . Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol. 2004; 35(6):647-53. DOI: 10.1007/s10735-004-2186-6. View

Laakso M, Tanner M, Isola J . Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol. 2006; 210(1):3-9. DOI: 10.1002/path.2022. View

Gong Y, Gilcrease M, Sneige N . Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol. 2005; 18(8):1015-21. DOI: 10.1038/modpathol.3800432. View

Sauer T, Wiedswang G, Boudjema G, Christensen H, Karesen R . Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?. APMIS. 2003; 111(3):444-50. DOI: 10.1034/j.1600-0463.2003.t01-1-1110210.x. View

10.

Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R . Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000; 18(21):3651-64. DOI: 10.1200/JCO.2000.18.21.3651. View

11.

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

12.

Bartlett J, Going J, Mallon E, Watters A, Reeves J, Stanton P . Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001; 195(4):422-8. DOI: 10.1002/path.971. View

13.

Saez A, Andreu F, Segui M, Bare M, Fernandez S, Dinares C . HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases. Breast. 2005; 15(4):519-27. DOI: 10.1016/j.breast.2005.09.008. View

14.

Bhargava R, Lal P, Chen B . Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?. Am J Clin Pathol. 2005; 123(2):237-43. View